Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells

DSpace/Manakin Repository

Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells

Citable link to this page

 

 
Title: Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells
Author: Chaudhuri, Arnab Ray; Callen, Elsa; Ding, Xia; Gogola, Ewa; Duarte, Alexandra A.; Lee, Ji-Eun; Wong, Nancy; Lafarga, Vanessa; Calvo, Jennifer A.; Panzarino, Nicholas J.; John, Sam; Day, Amanda; Crespo, Anna Vidal; Shen, Binghui; Starnes, Linda M.; de Ruiter, Julian R.; Daniel, Jeremy A.; Konstantinopoulos, Panagiotis A.; Cortez, David; Cantor, Sharon B.; Fernandez-Capetillo, Oscar; Ge, Kai; Jonkers, Jos; Rottenberg, Sven; Sharan, Shyam K.; Nussenzweig, André

Note: Order does not necessarily reflect citation order of authors.

Citation: Chaudhuri, A. R., E. Callen, X. Ding, E. Gogola, A. A. Duarte, J. Lee, N. Wong, et al. 2016. “Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells.” Nature 535 (7612): 382-387. doi:10.1038/nature18325. http://dx.doi.org/10.1038/nature18325.
Full Text & Related Files:
Abstract: Brca1- and Brca2-deficient cells have reduced capacity to repair DNA double-strand breaks (DSBs) by homologous recombination (HR) and consequently are hypersensitive to DNA damaging agents, including cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors. Here we show that loss of the MLL3/4 complex protein, PTIP, protects Brca1/2-deficient cells from DNA damage and rescues the lethality of Brca2-deficient embryonic stem cells. However, PTIP deficiency does not restore HR activity at DSBs. Instead, its absence inhibits the recruitment of the MRE11 nuclease to stalled replication forks, which in turn protects nascent DNA strands from extensive degradation. More generally, acquisition of PARPi and cisplatin resistance is associated with replication fork (RF) protection in Brca2-deficient tumor cells that do not develop Brca2 reversion mutations. Disruption of multiple proteins, including PARP1 and CHD4, leads to the same end point of RF protection, highlighting the complexities by which tumor cells evade chemotherapeutic interventions and acquire drug resistance.
Published Version: doi:10.1038/nature18325
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959813/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:30371082
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters